vtama Drug Patent Profile
✉ Email this page to a colleague
When do Vtama patents expire, and what generic alternatives are available?
Vtama is a drug marketed by Dermavant Sci and is included in one NDA. There are nine patents protecting this drug.
This drug has seventy-two patent family members in thirty-six countries.
The generic ingredient in VTAMA is tapinarof. One supplier is listed for this compound. Additional details are available on the tapinarof profile page.
DrugPatentWatch® Generic Entry Outlook for Vtama
Vtama will be eligible for patent challenges on May 23, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 13, 2038. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for vtama?
- What are the global sales for vtama?
- What is Average Wholesale Price for vtama?
Summary for vtama
| International Patents: | 72 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 60 |
| Patent Applications: | 88 |
| Drug Prices: | Drug price information for vtama |
| What excipients (inactive ingredients) are in vtama? | vtama excipients list |
| DailyMed Link: | vtama at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vtama
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for vtama
| Drug Class | Aryl Hydrocarbon Receptor Agonist |
| Mechanism of Action | Aryl Hydrocarbon Receptor Agonists |
US Patents and Regulatory Information for vtama
vtama is protected by nine US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of vtama is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting vtama
Topical pharmaceutical compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical pharmaceutical compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
Process for preparing tapinarof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting vtama
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dermavant Sci | VTAMA | tapinarof | CREAM;TOPICAL | 215272-001 | May 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Dermavant Sci | VTAMA | tapinarof | CREAM;TOPICAL | 215272-001 | May 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Dermavant Sci | VTAMA | tapinarof | CREAM;TOPICAL | 215272-001 | May 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Dermavant Sci | VTAMA | tapinarof | CREAM;TOPICAL | 215272-001 | May 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Dermavant Sci | VTAMA | tapinarof | CREAM;TOPICAL | 215272-001 | May 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Dermavant Sci | VTAMA | tapinarof | CREAM;TOPICAL | 215272-001 | May 23, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for vtama
When does loss-of-exclusivity occur for vtama?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 18365241
Patent: Process for preparing tapinarof
Estimated Expiration: ⤷ Sign Up
Patent: 23274224
Patent: PROCESS FOR PREPARING TAPINAROF
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2020009158
Patent: processo para o preparo de um composto, composto e composição farmacêutica
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 82115
Patent: PROCESSUS POUR LA PREPARATION DE TAPINAROF (PROCESS FOR PREPARING TAPINAROF)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 20001226
Patent: Proceso para preparar tapinarof.
Estimated Expiration: ⤷ Sign Up
Patent: 23000154
Patent: Proceso para preparar tapinarof; compuestos intermediarios; solvato de tapinarof; forma cristalina y composición farmacéutica que la comprende (sol. div. 202001226).
Estimated Expiration: ⤷ Sign Up
China
Patent: 1511357
Patent: PROCESS FOR PREPARING TAPINAROF
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 20007018
Patent: Proceso para preparar tapinarof
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 06725
Patent: PROCESSUS POUR LA PRÉPARATION DE TAPINAROF (PROCESS FOR PREPARING TAPINAROF)
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 4439
Patent: תהליך להכנת טפינארוף (Process for preparing tapinarof)
Estimated Expiration: ⤷ Sign Up
Patent: 4090
Patent: תהליך להכנת טפינארוף (Process for preparing tapinarof)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 12664
Estimated Expiration: ⤷ Sign Up
Patent: 66399
Estimated Expiration: ⤷ Sign Up
Patent: 21063100
Patent: タピナロフを調製するためのプロセス (PROCESS FOR PREPARING TAPINAROF)
Estimated Expiration: ⤷ Sign Up
Patent: 21169482
Patent: タピナロフを調製するためのプロセス (PROCESS FOR PREPARING TAPINAROF)
Estimated Expiration: ⤷ Sign Up
Patent: 21502333
Patent: タピナロフを調製するためのプロセス
Estimated Expiration: ⤷ Sign Up
Patent: 23002516
Patent: タピナロフを調製するためのプロセス
Estimated Expiration: ⤷ Sign Up
Patent: 24069233
Patent: タピナロフを調製するためのプロセス (PROCESS FOR PREPARING TAPINAROF)
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 20004785
Patent: PROCESO PARA PREPARAR TAPINAROF. (PROCESS FOR PREPARING TAPINAROF.)
Estimated Expiration: ⤷ Sign Up
Patent: 22015106
Patent: PROCESO PARA PREPARAR TAPINAROF. (PROCESS FOR PREPARING TAPINAROF.)
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 20116424
Patent: СПОСОБ ПОЛУЧЕНИЯ ТАПИНАРОФА
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 202002576T
Patent: PROCESS FOR PREPARING TAPINAROF
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 200087786
Patent: 타피나로프의 제조 방법
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering vtama around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Africa | 202007965 | TOPICAL PHARMACEUTICAL COMPOSITIONS | ⤷ Sign Up |
| Dominican Republic | P2017000270 | COMPOSICIONES FARMACÉUTICAS TÓPICAS | ⤷ Sign Up |
| Brazil | 112017024934 | composições farmacêuticas tópicas | ⤷ Sign Up |
| Hungary | E059066 | ⤷ Sign Up | |
| Australia | 2016263161 | Topical pharmaceutical compositions | ⤷ Sign Up |
| Hong Kong | 1245074 | 局部藥物組合物 (TOPICAL PHARMACEUTICAL COMPOSITIONS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
